Summary: PathAI adds FDA and EMA qualification for AIM-MASH

Why It Matters: PathAI has secured regulatory approval from both US and European agencies for its MASH clinical trial tool. This gives them a significant advantage in the global drug development market by providing a validated, "official" AI tool for researchers.

What Changed:

• Added a featured announcement about AIM-MASH AI Assist receiving FDA and EMA qualification.
• Updated the navigation menu to include "AI Product Solutions" under the BioPharma section.
• Renamed "Central Laboratory Services" to "Central Pathology Laboratory Operations."
• Added "AISight® Clinical Trials" to the service offerings.
• Updated the copyright year to 2026.